These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 3665338)

  • 1. Disposition kinetics of moclobemide, a monoamine oxidase-A enzyme inhibitor: single and multiple dosing in normal subjects.
    Schoerlin MP; Mayersohn M; Korn A; Eggers H
    Clin Pharmacol Ther; 1987 Oct; 42(4):395-404. PubMed ID: 3665338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cimetidine alters the disposition kinetics of the monoamine oxidase-A inhibitor moclobemide.
    Schoerlin MP; Mayersohn M; Hoevels B; Eggers H; Dellenbach M; Pfefen JP
    Clin Pharmacol Ther; 1991 Jan; 49(1):32-8. PubMed ID: 1988238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disposition kinetics of moclobemide, a new MAO-A inhibitor, in subjects with impaired renal function.
    Schoerlin MP; Horber FF; Frey FJ; Mayersohn M
    J Clin Pharmacol; 1990 Mar; 30(3):272-84. PubMed ID: 2312783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Absorption and disposition of moclobemide in patients with advanced age or reduced liver or kidney function.
    Stoeckel K; Pfefen JP; Mayersohn M; Schoerlin MP; Andressen C; Ohnhaus EE; Frey F; Guentert TW
    Acta Psychiatr Scand Suppl; 1990; 360():94-7. PubMed ID: 2248088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of moclobemide after single and multiple oral dosing with 150 milligrams 3 times daily for 15 days.
    Guentert TW; Tucker G; Korn A; Pfefen JP; Haefelfinger P; Schoerlin MP
    Acta Psychiatr Scand Suppl; 1990; 360():91-3. PubMed ID: 2248087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical pharmacokinetics of the monoamine oxidase-A inhibitor moclobemide.
    Mayersohn M; Guentert TW
    Clin Pharmacokinet; 1995 Nov; 29(5):292-332. PubMed ID: 8582117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoamine oxidase-A: pharmacodynamics in humans of moclobemide, a reversible and selective inhibitor.
    Holford NH; Guentert TW; Dingemanse J; Banken L
    Br J Clin Pharmacol; 1994 May; 37(5):433-9. PubMed ID: 7519866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of oral moclobemide in healthy human subjects and effects on MAO-activity in platelets and excretion of urine monoamine metabolites.
    Wiesel FA; Raaflaub J; Kettler R
    Eur J Clin Pharmacol; 1985; 28(1):89-95. PubMed ID: 3987791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of cytochrome P450 2D6 in the metabolism of moclobemide.
    Härtter S; Dingemanse J; Baier D; Ziegler G; Hiemke C
    Eur Neuropsychopharmacol; 1996 Aug; 6(3):225-30. PubMed ID: 8880082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of food intake on the relative bioavailability of moclobemide (Ro 11-1163).
    Schoerlin MP; Mayersohn M; Hoevels B; Eggers H; Dellenbach M; Pfefen JP
    J Neural Transm Suppl; 1988; 26():115-21. PubMed ID: 3283288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unaltered ibuprofen-induced faecal blood loss upon coadministration of moclobemide.
    Guentert TW; Schmitt M; Dingemanse J; Banken L; Jonkman JH; Oosterhuis B
    Drug Metabol Drug Interact; 1992; 10(4):307-22. PubMed ID: 1304448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Moclobemide excretion in human breast milk.
    Pons G; Schoerlin MP; Tam YK; Moran C; Pfefen JP; Francoual C; Pedarriosse AM; Chavinie J; Olive G
    Br J Clin Pharmacol; 1990 Jan; 29(1):27-31. PubMed ID: 2297459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-dose pharmacokinetics of the MAO-inhibitor moclobemide in man.
    Raaflaub J; Haefelfinger P; Trautmann KH
    Arzneimittelforschung; 1984; 34(1):80-2. PubMed ID: 6538424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of moclobemide, a new reversible monoamine oxidase inhibitor, on absorption and pressor effect of tyramine.
    Korn A; Da Prada M; Raffesberg W; Gasic S; Eichler HG
    J Cardiovasc Pharmacol; 1988 Jan; 11(1):17-23. PubMed ID: 2450251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switch in treatment from tricyclic antidepressants to moclobemide: a new generation monoamine oxidase inhibitor.
    Dingemanse J; Kneer J; Fotteler B; Groen H; Peeters PA; Jonkman JH
    J Clin Psychopharmacol; 1995 Feb; 15(1):41-8. PubMed ID: 7714227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: a panel study.
    Gram LF; Guentert TW; Grange S; Vistisen K; Brøsen K
    Clin Pharmacol Ther; 1995 Jun; 57(6):670-7. PubMed ID: 7781267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical pharmacology of moclobemide during chronic administration of high doses to healthy subjects.
    Dingemanse J; Wood N; Guentert T; Oie S; Ouwerkerk M; Amrein R
    Psychopharmacology (Berl); 1998 Nov; 140(2):164-72. PubMed ID: 9860107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of moclobemide in male, virgin female, pregnant and nursing rats.
    Oie S; Guentert TW; Tolentino L; Hermodsson G
    J Pharm Pharmacol; 1992 May; 44(5):413-8. PubMed ID: 1359056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initial monoamine oxidase-A inhibition by moclobemide does not predict the therapeutic response in patients with major depression. A double blind, randomized study.
    Radat F; Berlin I; Spreux-Varoquaux O; Elatki S; Ferreri M; Puech AJ
    Psychopharmacology (Berl); 1996 Oct; 127(4):370-6. PubMed ID: 8923574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Species-specific biotransformation of moclobemide: a comparative study in rats and humans.
    Schoerlin MP; Da Prada M
    Acta Psychiatr Scand Suppl; 1990; 360():108-10. PubMed ID: 2248061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.